ChiCTR2400093752 版本V1.0 版本创建时间2024/12/11 15:26:57 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2400093752 

最近更新日期:

Date of Last Refreshed on:

2024-12-11 15:25:54 

注册时间:

Date of Registration:

2024-12-11 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

新生儿持续性肺动脉高压在线注册:多中心、开放性、观察性队列研究

Public title:

Persistent Pulmonary Hypertension of the Newborn Online Registry: a multicentre, open, observational cohort study

注册题目简写:

English Acronym:

研究课题的正式科学名称:

新生儿持续性肺动脉高压在线注册:多中心、开放性、观察性队列研究

Scientific title:

Persistent Pulmonary Hypertension of the Newborn Online Registry: a multicentre, open, observational cohort study

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

黄艳 

研究负责人:

张炼 

Applicant:

Huang Yan 

Study leader:

Zhang Lian 

申请注册联系人电话:

Applicant telephone:

+86 136 9169 9870

研究负责人电话:

Study leader's telephone:

+86 186 6602 8994

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

530135565@qq.com

研究负责人电子邮件:

Study leader's E-mail:

zhliande@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

广东省深圳市宝安区新安街道玉律路56号

研究负责人通讯地址:

广东省深圳市宝安区新安街道玉律路56号

Applicant address:

56 Yulv Road, Baoan District, Shenzhen, Guangdong, China

Study leader's address:

56 Yulv Road, Baoan District, Shenzhen, Guangdong, China

申请注册联系人邮政编码:

Applicant postcode:

518100

研究负责人邮政编码:

Study leader's postcode:

518100

申请人所在单位:

深圳市宝安区妇幼保健院

Applicant's institution:

Shenzhen Baoan Women's and Children's Hospital

研究负责人所在单位:

深圳市宝安区妇幼保健院

Affiliation of the Leader:

Shenzhen Baoan Women's and Children's Hospital

是否获伦理委员会批准:

是/Yes

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

LLSC-2024-03-10-22-KS

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

深圳市宝安区妇幼保健院医学伦理委员会

Name of the ethic committee:

Research Ethics Committee of Shenzhen Baoan Women's and Children's Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2024-10-21 00:00:00

伦理委员会联系人:

程晓莉

Contact Name of the ethic committee:

Cheng Xiaoli

伦理委员会联系地址:

广东省深圳市宝安区新安街道玉律路56号

Contact Address of the ethic committee:

56 Yulv Road, Baoan District, Shenzhen, Guangdong, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 755 2786 3999

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

深圳市宝安区妇幼保健院

Primary sponsor:

Shenzhen Baoan Women's and Children's Hospital

研究实施负责(组长)单位地址:

广东省深圳市宝安区新安街道玉律路56号

Primary sponsor's address:

56 Yulv Road, Baoan District, Shenzhen, Guangdong, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

广东

市(区县):

深圳

Country:

China

Province:

Guangdong

City:

Shenzhen

单位(医院):

宝安区妇幼保健院

具体地址:

广东省深圳市宝安区新安街道玉律路56号

Institution
hospital:

Shenzhen Baoan Women's and Children's Hospital

Address:

56 Yulv Road, Baoan District, Shenzhen, Guangdong, China

经费或物资来源:

Source(s) of funding:

None

Target disease:

Persistent Pulmonary Hypertension of the Newborn

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

队列研究 

Study design:

Cohort study 

研究目的:

研究目的:(1)建立深圳新生儿持续性肺动脉高压(PPHN)队列,构建PPHN专病数据库。(2)全面调查深圳地区PPHN流行病学特点、危险因素、救治管理和结局。(3)建立PPHN早期诊断、近期及远期不良结局预测模型,实现早期诊断和提前干预,减少重症PPHN、死亡和远期不良结局的发生,提高新生儿生存质量。  

Objectives of Study:

Objectives: (1) To establish a cohort of neonatal persistent pulmonary hypertension (PPHN) in Shenzhen and to construct a PPHN disease database. (2) To comprehensively investigate the epidemiological characteristics, risk factors, treatment management and outcomes of PPHN in Shenzhen. (3) Establish a prediction model for early diagnosis, short-term and long-term adverse outcomes of PPHN, achieve early diagnosis and early intervention, reduce the occurrence of severe PPHN, death and long-term adverse outcomes, and improve the quality of life of neonates.

药物成份或治疗方案详述:

无 

Description for medicine or protocol of treatment in detail:

None 

纳入标准:

(1)出生的胎龄≥22周的新生儿; (2)生后7天内入住NICU; (3)存在呼吸困难需无创/有创呼吸机支持; (4)吸氧浓度>40%。

Inclusion criteria

1.Newborns born with a gestational age of >= 22 weeks; 2. Admitted to the NICU within 7 days after birth; 3. Respiratory distress requiring noninvasive/invasive ventilator support; 4. Oxygen concentration> 40%.

排除标准:

1.紫绀型先天性心脏病; 2.伴有其他重要畸形(指一般不引起 PPHN、但容易导致患儿死亡或者家长放弃治疗的畸形,如皮-罗综合征、马凡综合征等) 3.入院前明确有严重出血,如肺出血、≥2级颅内出血 (IVH) 的患者; 4.染色体病 5.遗传代谢性疾病; 6.自动出院或转院,且转入医院不在参与中心; 7.拒绝参加者。

Exclusion criteria:

1. Cyanotic congenital heart disease; 2. Children born with significant malformations (malformations that do not generally cause PPHN but that predispose the child to death or parental abandonment of treatment, e.g., Pierre-Robin Syndrome, Marfan Syndrome, etc.); 3. Patients with severe hemorrhage, e.g., pulmonary hemorrhage, grade >=2 intracranial hemorrhage (IVH), clearly identified prior to admission; 4. Chromosomal diseases; 5. Patients with metabolic disorders; 6. Automatic discharge or transfer to a hospital other than a participating center; 7.Those who refused to participate in the study.

研究实施时间:

Study execute time:

From 2025-01-01 00:00:00 To 2029-12-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2025-01-01 00:00:00 To 2029-12-31 00:00:00  

干预措施:

Interventions:

组别:

PPHN无应用iNO治疗

样本量:

250

Group:

PPHN was not treated with iNO in the group

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

组别:

PPHN应用iNO治疗

样本量:

250

Group:

PPHN treated with iNO treatment group

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

广东 

市(区县):

深圳市 

Country:

China 

Province:

Guangdong 

City:

Shenzhen 

单位(医院):

深圳市宝安区妇幼保健院 

单位级别:

三甲 

Institution
hospital:

Shenzhen Baoan Women's and Children's Hospital

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

广东 

市(区县):

深圳市 

Country:

China 

Province:

Guangdong 

City:

Shenzhen 

单位(医院):

深圳市人民医院 

单位级别:

三甲 

Institution
hospital:

Shenzhen People's Hospital

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

广东 

市(区县):

深圳市 

Country:

China 

Province:

Guangdong 

City:

Shenzhen 

单位(医院):

深圳市妇幼保健院 

单位级别:

三甲 

Institution
hospital:

Shenzhen Maternal and Child Health Hospital

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

广东 

市(区县):

深圳市 

Country:

China 

Province:

Guangdong 

City:

Shenzhen 

单位(医院):

深圳市儿童医院 

单位级别:

三甲 

Institution
hospital:

Shenzhen Children's Hospital

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

广东 

市(区县):

深圳市 

Country:

China 

Province:

Guangdong 

City:

Shenzhen 

单位(医院):

深圳市龙岗区妇幼保健院 

单位级别:

三甲 

Institution
hospital:

Longgang District Maternity & Child Healthcare Hospital of Shenzhen City

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

广东 

市(区县):

深圳市 

Country:

China 

Province:

Guangdong 

City:

Shenzhen 

单位(医院):

深圳市光明区人民医院 

单位级别:

三甲 

Institution
hospital:

Shenzhen Guangming District People's Hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

早期死亡

指标类型:

主要指标

Outcome:

early death

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

中-重度神经发育障碍

指标类型:

主要指标

Outcome:

Moderate to severe neurodevelopmental disorders

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

有创呼吸机通气时间

指标类型:

次要指标

Outcome:

Duration of invasive ventilator ventilation

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

吸氧时间

指标类型:

次要指标

Outcome:

Duration of oxygen therapy

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

生长受限

指标类型:

次要指标

Outcome:

restriction in growth

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

听力损害

指标类型:

次要指标

Outcome:

hearing impairment

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

视力损害

指标类型:

次要指标

Outcome:

visual impairment

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

运动损害

指标类型:

次要指标

Outcome:

motion damage

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

Griffiths评分

指标类型:

次要指标

Outcome:

Griffiths score

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

晚期死亡

指标类型:

主要指标

Outcome:

late deaths

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

none

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age years
最大 Max age years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

none

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

None

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

本项目计划2029年12月结束,项目研究结束以后,联系研究者邮箱获得

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

This project is planned to end in December 2029, and after the end of the project research, please contact the investigator's email address

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

CRF

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

CRF

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2024-12-11 15:25:54